|
OGAWA Tetsuya
Department School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine Position Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Left ventricular end-diastolic diameter is an independent predictor of mortality in hemodialysis patients. |
| Journal | Formal name：Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy Abbreviation：Ther Apher Dial ISSN code：1744-9987(Electronic)1744-9979(Linking) |
| Volume, Issue, Page | 16(2),pp.134-41 |
| Author and coauthor | Inoue Tomoko†, Ogawa Tetsuya, Iwabuchi Yuko, Otsuka Kuniaki, Nitta Kosaku |
| Authorship | 2nd author |
| Publication date | 2012/04 |
| Summary | Left ventricular (LV) function is impaired in most hemodialysis (HD) patients. We conducted an observational cohort study to investigate whether LV end-diastolic diameter (LVDd) could predict all-cause mortality in a cohort of 166 HD patients. The LVDd values (5.06 ± 0.64 cm) of the non-survivor group were significantly greater than in the survivor group (4.78 ± 0.71 cm). The area under the receiver operating characteristic curve for an LVDd cut-off value of 5.01 cm was 0.6145 (P = 0.0234).The sensitivity and specificity of the LVDd threshold of 5.01 cm were 75.7% and 50.4%, respectively. The 4-year survival rate was significantly lower in the group with LVDd ≥ 5.01 cm than in the group with LVDd<5.01 cm (log-rank test, P = 0.0047). Multivariate analysis with adjustments for clinical and echocardiographic parameters showed that increased LVDd was an independent predictor of all-cause mortality (hazard ratio 2.363, 95% CI 1.320-4.228, P = 0.0013). The results of the present study showed that increased LVDd predicts the all-cause mortality of chronic HD patients better than other echocardiographic parameters. Our findings suggest that LVDd measurements may be helpful for risk stratification and providing therapeutic direction for the management of HD patients. |
| DOI | 10.1111/j.1744-9987.2011.01048.x |
| Document No. | 22458391 |